Role of D2 gastrectomy in gastric cancer with clinical para-aortic lymph node metastasis

Table 6 Long-term survivors (more than 3 years)

Therapy	PAN			Response				Survival
	Target	SN		Overall	Primary	PAN		SR	OS	PFS	Status
C+S+C	NT	1		NE	PR	CR			65.1	65.1	Alive
C+S+C	NT	1		PR	PR	CR			72.4	72.4	Alive
C+S+C	NT	1		NE	PR	CR			62.1	62.1	Alive
C+S+C	NT	2		CR	CR	CR		L	52.8	16.8	Alive
C+S+CRT	NT	2		NE	SD	NN			70.1	70.1	Alive
C+S+CRT	NT	2		PR	PR	CR		PAN	50.7	16.2	Dead
C	T	3		CR	CR	CR		NA	37.8	20.9	Alive
C	T	3		PR	PR	NN		NA	36.3	36.3	Alive

C: Chemotherapy; S: D2 gastrectomy; CRT: Chemoradiotherapy; PAN: Para-aortic node; NT: Non-target lesions; SN: Para-aortic node station involved number; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable; NC: Non-complete response; SR: Sites of recurrence; L: Lung; OS: Overall survival; PFS: Progression-free survival.